pacman schreef op 8 januari 2021 11:54:
W.E, omdat tocilizumab bij Roche hoort, ze hebben 2 trials CORO lopen
Actemra/RoACTEMRA (tocilizumab) is a humanised monoclonal antibody to the interleukin-6 receptor, inhibiting the activity of interleukin-6 and is being investigated in the treatment of Covid-19 pneumonia in combination with remdesivir.
en
Actemra/RoACTEMRA (tocilizumab) is a humanised monoclonal antibody to the interleukin-6 receptor, inhibiting the activity of interleukin-6 and is being investigated in the treatment of Covid-19 pneumonia.
allebei fase 3, en wat nu met aandeel gebeurt zou je ook kunnen toeschrijven aan de huisbankier van Roche...??
nu mijn vraag/gedachte , kijkt Roche mee Pharming/Basel/Uni's